WW4: A NEW APPROACH TO DISEASE MODELING WITH NUMEROUS COMPARATORS AND MULTIPLE DECISION TREES  by Becker, R et al.
Abstracts 189
ties encountered and offer recommendations for using
such databases to examine provider prescribing prac-
tices, patient compliance, and outcomes of ADHD-related
care. The following methodological issues will be dis-
cussed: 1) determining the presence of specific psychiatric
disorders and their comorbidities from pharmacy benefits
databases; 2) using pharmacy benefits databases and pa-
tient telephone and mail surveys to distinguish discontin-
ued psychotropic treatment from patient noncompliance
and medication switching; 3) applying health services uti-
lization and pharmacy databases to determine small area
variation in ADHD care; 4) examining the impact of be-
havioral health care carve-outs on analyses of patient
outcomes; 5) employing findings to benchmark existing
quality of care, calculate rates of provider adherence to
guidelines, identify best practices, and evaluate impact of
interventions on outcomes of patients with ADHD.
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USING LINKABLE CLINICAL AND 
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OUTCOMES RESEARCH: SELECTED CASE 
STUDIES FROM ONCOLOGY AND
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OBJECTIVES: The objectives of this workshop are to de-
scribe various types of linkable clinical and administra-
tive claims data, review selected case studies, and high-
light the strengths and limitations of these databases.
PARTICIPANTS WHO WOULD BENEFIT: Those in-
volved in planning, designing, implementing, and using
data from retrospective database studies would benefit
from this workshop.
Administrative claims are increasingly used for outcomes
research studies, despite known limitations associated
with data reliability and validity, and a lack of clinical
content. In recent years, efforts have been made to link
claims to other sources, such as disease registries and
clinical laboratory files, to create richer databases for re-
search purposes. These linked data sources offer the po-
tential for improved accuracy in case identification and
outcomes ascertainment. For example, study patients can
be selected based on their presence in a disease registry
instead of relying on diagnoses reported on medical claim
forms, and clinical laboratory files can be used to evalu-
ate the success or failure of therapy. In this workshop, we
will review, via case studies from oncology and diabetes,
the content of linkable clinical and claims databases, the
specific ways in which such data have been used in pub-
lished outcomes studies, and the remaining limitations of
this record linkage approach. Participants will learn how
clinical data can be applied to strengthen studies of treat-
ment costs and the burden of illness, and they will gain
an appreciation of the improvements that linked data
sources can make to the pharmacoeconomics and out-
comes research fields. One case study will review applica-
tions of the SEER-Medicare database, which includes a
linkage between cancer registry data and Medicare ad-
ministrative claims for approximately 14% of U.S. cancer
cases across 17 diverse regions. The other illustration will
describe published studies of the economic benefits of im-
proving glycemic control among diabetes patients, in
which claims data from several managed-care organiza-
tions were linked to glycosylated hemoglobin test results.
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OBJECTIVES: The purposes of the workshop are to
demonstrate a systematic method to compare published
models developed for a same disease and to point out the
importance of validation of model structure, data input
and outcomes.
PARTICIPANTS WHO WOULD BENEFIT: Pharmaco-
economic and outcomes researchers involved in modeling
and/or in the area of DVT.
In the clinical and health economic literature, 11 different
models from different researchers are published in the
area of DVT prevention with heparins. These models
generally compare standard heparin with one of the low
molecular weight heparins in order to assess the health
economic consequences of better prevention at a higher
price. All models differ in many aspects of study design
and methodology: perspective, target audience, patient
population, patient subpopulations, choice of compara-
tor(s) and justification of this choice, medical manage-
ment patterns and corresponding decision trees, clinical
data input and reporting, economic data input and re-
porting, dealing with uncertainties, validation, conclu-
sions and extrapolations. This lack of uniformity in de-
sign and methods within a same research topic leads to
incomparable outcomes and conclusions. The workshop
is designed to discuss with the audience the strengths and
weaknesses of all models, and to have the audience sug-
gest solutions for better design, reporting and communi-
cations of results in this area and for decision models in
general. A novel consensus method, leading to a new
model, attempting to bring together the best elements of ex-
isting models, is proposed for discussion with the audience.
WW4
A NEW APPROACH TO DISEASE MODELING 
WITH NUMEROUS COMPARATORS AND 
MULTIPLE DECISION TREES
Becker R1, Noe L1, Gore M2, Martino S3
1Ovation Research Group, Highland Park, IL, USA; 2Avalon 
Health Solutions, Wilmington, DE, USA; 3John Wayne Cancer 
Institute, Santa Monica, CA, USA
190 Abstracts
OBJECTIVES: The objective of this workshop is to de-
scribe the approach used in developing a comprehensive,
multi-national breast cancer treatment model. This dis-
ease model was developed for six international markets—
U.S., U.K., Germany, Japan, France, and Italy—and in-
cludes over 70 treatment comparators used in 24 unique
decision trees. The model’s flexibility, with nearly 350
variable cost components related to the diagnosis, treat-
ment, and outcomes of breast cancer, allows for an ex-
amination of the effect of varying cost and probability
scenarios to reflect a multitude of country-specific treat-
ment practices and international practice variations.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers involved in the development of international clinical
and economic decision analysis models.
A disease treatment model can be a useful tool for com-
prehensively evaluating the clinical and economic aspects
of a specific disease. This workshop will explain the steps
involved in building the model, including: Use of ac-
cepted clinical guidelines to develop treatment pathways
and the use of expert-opinion to reflect variations in ac-
tual current practice Probability data collection for over
144 million decision nodes Cost data collection for all
treatments and cost components. Computer software
used to program the model. Interaction of clinical end-
point, cost, and clinical pathway modules. Type of results
generated (e.g., database queries, sequence queries, cost-
effectiveness analysis). Limitations and possible applica-
tions to other diseases Participants in this workshop will
have an opportunity to suggest customized queries to be
answered by the model.
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OBJECTIVES: Cost-effectiveness analysis requires esti-
mating gains in life expectancy from effective treatments.
Survival is not an endpoint in many clinical trials, be-
cause of limited follow-up intervals or statistical power.
If databases linking survival to the surrogate markers
used in the trials are not available, fragmentary published
data based on follow-up studies may suffice. This work-
shop illustrates methods for using limited published data
to estimate life expectancy gains. Participants will be en-
couraged to share their own experiences in modeling life
expectancy.
PARTICIPANTS WHO WOULD BENEFIT: Analysts
who want to estimate cost-effectiveness based on limited
published data.
This workshop illustrates methods for using limited pub-
lished data to estimate life expectancy gains. The exam-
ple concerns AIDS wasting, in which patients with HIV
infection experience significant weight loss. Treatments
such as human growth hormone (HGH) and anabolic
steroids have been found effective in retarding weight
loss or even restoring body weight in patients with AIDS
wasting. Published survival curves stratified by weight
change from baseline (in ranges such as 10% to 5%)
and CD4 cell count were found in the literature. A clini-
cal trial of HGH reported means and standard deviations
of weight change from baseline with drug and with pla-
cebo. Our task was to use these data to estimate the life
expectancy gain with HGH in patients stratified by CD4
cell count. The presenters will demonstrate the following
analytic steps: (1) estimating probability distributions of
weight change from the clinical trial and using these to
estimate the probability that patients would experience
each range of weight change; (2) estimating areas under
the published survival curves to estimate truncated life
expectancies by range of weight change; (3) using the
DEALE method to extrapolate survival and life expect-
ancy beyond the trial follow-up period; (4) combining
steps (1)-(3) to estimate the gain in life expectancy attrib-
utable to treatment; and (5) applying discounting to the
survival analysis and life expectancy calculations. As with
all life expectancy estimates mediated by surrogate mark-
ers, there is no “proof” that weight change caused by
treatment will translate into life expectancy gains. In the
absence of direct evidence of a survival benefit, however,
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OBJECTIVES: The objective of this workshop will be to
develop an understanding of conjoint analysis methodol-
ogy, and how it can be used to conduct cost-utility analy-
sis and cost-benefit analysis by capturing patient prefer-
ences.
PARTICIPANTS WHO WOULD BENEFIT: Analysts
involved in the conduct of pharmacoeconomic studies,
particularly those interested in the patient’s perspective.
Cost-utility analysis (CUA) and cost-benefit analysis
(CBA) are alternate analytical frameworks that can be
used to evaluate health interventions. CUA uses a non-
monetary metric, such as quality-adjusted life years
(QALYs), to value health benefits. In CBA, both costs
and benefits are measured in monetary terms. Conjoint
analysis can be used to estimate the benefits of an inter-
vention in either monetary or non-monetary terms and
can be used in both CUA and CBA. In this workshop, we
